Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer

Reuters12-15

Actuate <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer

Actuate Therapeutics Inc. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in combination with platinum chemotherapy (carboplatin or cisplatin), with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research (PMID: 41065505), show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601946) on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591417156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591417156","market":"fut","top_or_hot":-1,"title":"Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in combination with platinum chemotherapy (carboplatin or cisplatin), with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research (PMID: 41065505), show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601946) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-15 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ACTU\">Actuate Therapeutics Inc</a>. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in combination with platinum chemotherapy (carboplatin or cisplatin), with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research (PMID: 41065505), show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601946) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLtyvkh:1","article_id":"2591417156","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591417156","pubTimestamp":1765806314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actuate Therapeutics Inc. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta  inhibitor, in combination with platinum chemotherapy , with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research , show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gene","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","ACTU":"Actuate Therapeutics Inc","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Actuate Therapeutics报告Elraglusib治疗转移性唾液腺癌的积极II期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ACTU":0.9},"content_text":"Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Metastatic Salivary Gland Cancer\n    \n\nActuate Therapeutics Inc. has announced the publication of new Phase II clinical trial data evaluating elraglusib, a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in combination with platinum chemotherapy (carboplatin or cisplatin), with or without sequential pembrolizumab immunotherapy, for patients with advanced, metastatic salivary gland cancers. The results, published in Clinical Cancer Research (PMID: 41065505), show a median overall survival of 18.6 months, with 40% of patients alive at two years. The study enrolled 32 patients, including both adenoid cystic carcinoma (47%) and non-ACC (53%) subtypes, in partnership with the Dana-Farber Cancer Institute. Findings suggest that nuclear GSK-3β expression may help identify patients most likely to benefit from this treatment approach. The data have already been published and are available for review.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9601946) on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591417156","isCrawlerRequest":true}